Showing results for : nuclear medicine therapy

Is PRRT Safe for you?

My last article (Which patients can benefit with PPRT?) summed up the fundamentals of Nuclear Medicine PRRT and which patients may benefit from this therapy. Today, I shall be giving you a low down on PRRT again, and we shall cover some details

Read more
225Ac-PSMA-617 – A New Beginning in the Treatment of Chemotherapy-Naive Prostate Cancer Patients

For advanced prostate cancer patients or metastatic castration-resistant prostate cancer (mCRPC) patients, conventional treatment modalities, such as surgery, chemotherapy etc. might not prove to be highly effective in terms of controlling the spread of the cancer. This is where Nuclear Medicine and Molecular Imaging are playing an important part in the management of cancer and that too in a personalized manner.

Read more
Lowest Cost of Lu177 PSMA Therapy

For prostate cancer patients who have become refractory to conventional therapy, the department of Nuclear Medicine & Molecular Imaging at the Fortis Memorial Research Institute (FMRI) in India’s Gurugram is not only one of the World’s most advanced Nuclear Medicine Centre but is also the centre that offers the lowest cost for Lu177 PSMA Therapy.

Read more
What is Transarterial Radioembolization (TARE)

TARE is a palliative treatment (it means that it does not provide a cure) that helps slow down the disease growth and also helps alleviate symptoms. It is often used as a treatment option for patients who cannot undergo other treatment options such as liver surgery or liver transplantation.

Read more
An In-Depth look at Prostate Cancer

Cancer is an abnormal cellular growth in a specific body region that is able to spread internally and cover other areas. If left untreated, it causes a number of life-threatening conditions that may even lead to fatality.

Read more
Castrate Resistant Prostate Cancer Treatment – Ac225 PSMA Therapy (Targeted Alpha Therapy)

In the past one year, the Nuclear Oncology Experts team at the Department of Nuclear Medicine at Fortis Memorial Research Institute has treated 30 new patients of Castrate Resistant Prostate Cancer (CRPC) with Ac225 PSMA Therapy (Targeted Alpha Therapy). And the results are similar to the results being achieved by most good Nuclear Medicine Centres across the world – 75-80% of the patients have shown evidences of a significant Radiological and Biochemical Response with prolonged duration of response.

Read more